UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Continued improvement in myocardial T2(star) over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload

Pennell, DJ; Porter, JB; Cappellini, MD; Chan, LL; El-Beshlawy, A; Aydinok, Y; Ibrahim, H; ... Taher, A; + view all (2011) Continued improvement in myocardial T2(star) over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Haematologica - The Hematology Journal , 96 (1) 48 - 54. 10.3324/haematol.2010.031468. Green open access

[thumbnail of 48.full.pdf]
Preview
PDF
48.full.pdf

Download (384kB)

Abstract

Background:The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with beta-thalassemia major in the cardiac sub-study of the EPIC trial.Design and MethodsEligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox, with the primary endpoint being the change in T2* from baseline to two years.ResultsBaseline myocardial T2* was severe (>5 to <10 ms) in 39 patients, and moderate-to-mild (10 to <20 ms) in 62 patients. Mean deferasirox dose was 33.1+/-3.7 mg/kg/d in the one-year core study increasing to 36.1+/-7.7 mg/kg/d during the second year of treatment. Geometric mean myocardial T2* increased from a baseline of 11.2 to 14.8 ms at two years (P<0.001). In patients with moderate-to-mild baseline T2*, an increase was seen from 14.7 to 20.1 ms, with normalization (20 ms) in 56.7% of patients. In those with severe cardiac iron overload at baseline, 42.9% improved to the moderate-to-mild group. The incidence of drug-related adverse events did not increase during the extension relative to the core study and included (>= 5%) increased serum creatinine, rash and increased alanine aminotransferase.ConclusionsContinuous treatment with deferasirox for two years with a target dose of 40 mg/kg/d continued to remove iron from the heart in patients with beta-thalassemia major and mild, moderate and severe cardiac siderosis. (Clinicaltrials.gov identifier: NCT 00171821)

Type: Article
Title: Continued improvement in myocardial T2(star) over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload
Open access status: An open access version is available from UCL Discovery
DOI: 10.3324/haematol.2010.031468
Publisher version: http://dx.doi.org/10.3324/haematol.2010.031468
Language: English
Additional information: Obtained from Haematologica/the Hematology Journal website http://www.haematologica.org. This article is published under under a Creative Commons Attribution 3.0 License (CC BY 3.0).
Keywords: beta-thalassemia major, cardiac iron overload, deferasirox, iron chelation, myocardial T2*, magnetic-resonance, deferoxamine, survival, deferiprone, transfusion, trial
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery.ucl.ac.uk/id/eprint/1307473
Downloads since deposit
90Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item